Interestingly, retrospective secondary analysis of a large-scale clinical trial of a monoclonal antibody targeting IL-1β for cardiovascular disease found reduced incidence of hip and knee replacement in patients with high C-reactive protein, suggesting a potential effect on OA progression in an inflammatory setting (296). This evidence concerns the gene CRP and cardiovascular disorder.